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Background: Patients showed a different response following intravenous midazolam injection. Some children 
showed irritability or were not sedated by midazolam. We hypothesized that there may be genetic variations of the 
MDR1 gene, based on the response to midazolam.
Methods: One hundred and ninety-three pediatric patients were recruited in this study. Midazolam (0.1 mg/kg) was 
injected intravenously before surgery. Anxiety score (activity, vocalizations, emotional expressivity, state of apparent 
arousal) was checked before and 5 minutes after midazolam injection. In addition, other manifestations after 
midazolam injection were recorded. After anesthesia, 2 ml of blood was sampled. Children were genotyped MDR1. 
Haplotype was analyzed using the software package PHASE, version 2.0. 
Results: The observed frequencies of MDR1 haplotype of TTT, TGC, CAC, CGC were 0.334, 0.205, 0.182 and 0.225, 
respectively. There was no significant correlation between the response of midazolam and the MDR1 haplotype of 
TTT, TGC, CAC or CGC (P = 0. 98). 
Conclusions: Genotyping of MDR1 may not be related to the response of midazolam in children. (Korean J 
Anesthesiol 2012; 62: 332-336)
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Introduction
Midazolam is a short-acting drug in the benzodiazepine class 
that is used for inducing sedation and amnesia before medical 
procedures, or anesthesia [1,2]. Sometimes, patients showed a 
paradoxical reaction such as crying, restlessness or vocalization 
after midazolam administration [3]. Kain et al. [4] reported that 
when children received midazolam as a premedication, some 
of them showed a paradoxical response and the degree of this 
response was related with the child’s age or anxiety level. To 
explain this paradoxical reaction, a change in the activation 
of GABA receptors [5] or genetic variation of benzodiazepine 
receptors was suggested [6]. 
P-glycoprotein (permeability glycoprotein, P-pg) is a well-
characterized ABC-transporter of the MDR/TAP subfamily. 
It is a 170 kDa trans-membrane glycoprotein encoded by the 
multidrug resistance 1 (MDR1 or ABCB1 gene). The function of 
P-pg is absorption, distribution or elimination of drugs. There 
are more than 28 of genetic variants of P-pg [7]. Polymorphism 
of the MDR 1 gene can cause refractoriness of anti-epileptic 
drugs [8], or resistance to steroids in early nephritic syndromes 
[9]. Based on this, a patient‘s responses to midazolam correlates 
with MDR 1 gene polymorphism. In this study, we administered 
midazolam preoperatively, observed the patient response and 
searched for a relationship with MDR1 gene polymorphism. 
Materials and Methods
After approval by the Institutional Ethics Committee, 193 
American Society of Anesthesiologists (ASA) I-II infants and 
children, aged from 2 to 12 years undergoing strabismus surgery, 
were enrolled in this study. Informed consent was obtained 
from the parents of all infants and children. Exclusion criteria 
included ASA status III-V, upper respiratory infection within 
4 weeks, history of neurologic disease or history of genetic 
disorder.
After fasting according to age (less than 36 months: 6 hours, 
more than 36 months: 8 hours), the patient arrived at the 
operating room without premedication. Before administration 
of midazolam, the patient was checked for consciousness. 
Every patient was clear and anxiety degree was measured by 
modified Yale preoperative anxiety scale (mYPAS, Table 1) 
before midazolam injection. Midazolam 0.1 mg/kg was admini-
stered and then a patient was observed for five minutes An 
anesthesiologist, who measured anxiety degree before injecting 
midazolam, measured and recorded anxiety degree again with 
mYPAS after injecting midazolam five minutes later. Sedation 
or anxiety degree was always measured with parents attending. 
After mYPAS was measured five minutes later, a patient was 
transferred to the operation room immediately. Then, electro-
cardiography, non-invasive blood pressure, oxygen saturation, 
Table 1. Modified Yale Preoperative Anxiety Scale (mYPAS) Assessments
Domain: Activity
    1. Looking around, curious, playing with toys, reading (or other age-appropriate behavior); moves around holding area/treatment room to 
get toys or go to parent; may move toward OR equipment
    2. Not exploring or playing, may look down, may fidget with hands or suck thumb (blanket); may sit close to parent while waiting, or play 
has a definite manic quality 
    3. Moving from toy to parent in unfocused manner, non–activity-derived movements, frenetic/frenzied movement or play; squirming, 
moving on table, may push mask away
    4. Actively trying to get away, pushes with feet and arms, may move whole body; in waiting room, running around unfocused, not looking 
at toys or will not separate from parent
Domain: Vocalizations
    1. Reading (nonvocalizing appropriate to activity), asking questions, making comments, babbling, laughing, readily answers questions but 
may be generally quiet; child too young to talk in social situations or too engrossed in play to respond
    2. Responding to adults but whispers, “baby talk,” only head nodding 
    3. Quiet, no sounds or responses to adults
    4. Whimpering, moaning, groaning, silently crying 
    5. Crying or may be screaming “no” 
    6. Crying, screaming loudly, sustained (audible through mask) 
Domain: Emotional Expressivity
    1. Manifestly happy, smiling, or concentrating on play 
    2. Neutral, no visible expression on face 
    3. Worried (sad) to frightened, sad, worried, or tearful eyes 
    4. Distressed, crying, extremely upset, may have wide eyes 
Domain: State of Apparent Arousal 
    1. Alert, looks around occasionally, notices/watches anesthesiologist (could be relaxed) 
    2. Withdrawn child sitting still and quiet, may be sucking on thumb or face turned in to adult 
    3. Vigilant looking quickly all around, may startle to sounds, eyes wide, body tense
    4. Panicked whimpering, may be crying or pushing others away, turns away334 www.ekja.org
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partial pressure of carbon dioxide and sevofluran concentration 
were monitored. Atropine 0.02 mg/kg (maximum dose 0.5 mg) 
were administered to every patient and then, thiopental 6 mg/
kg was administered intravenously. After losing consciousness, 
the patients were ventilated manually with 8 vol% sevoflurane 
and 100% oxygen. For muscle relaxation, rocuronium 0.6 mg/
kg was administered. During the induction of anesthesia, 2 
ml of venous blood was collected for measuring midazolam 
concentration and conducting a genotype test. The blood was 
stored in a vacuum EDTA tube at -70
oC. After appropriate 
muscle relaxation was established, insertion of a larynx mask or 
endotracheal intubation was performed. Then, anesthesia was 
maintained with 2-3 vol% sevoflurane in 50% oxygen and 50% 
nitrous oxide. After surgery, muscle relaxation was reversed and 
a patient was transferred to the recovery room after extubation 
with complete awakening.
According to a previous study, a non-responder was decided 
when activity was more than 3, vocalization was more than 4, 
emotional expressivity was more than 3 and arousal was more 
than 3 in mYPAS [4]. When even one of four items was decided 
as a non-responder, the patient was decided as a non-responder 
group in this study. After administering midazolam, a case of 
other responses, which were not classified in mYPAS, were also 
recorded.
DNA extraction
General anesthesia was maintained using a conventional 
method and 2 ml of venous blood was collected into a tube 
containing EDTA and stored at refrigeration temperatures. 
The sample was centrifuged for a genotype test and genomic 
DNA was extracted by QIAamp DNA Mini kit (Qiagen Inc., 
Valencia, CA) using the leukocyte layer. The blood sample was 
centrifuged at 2,500 rpm for 10 minutes and then the leukocyte 
layer was separated. In the leukocyte layer, 200 μl was collected 
and mixed with QIAGEN protease 20 μl and AL buffer 200 
μl, after which it was shaken by vortex mixer for 15 seconds. 
After incubation at 56
oC for 10 minutes, the mixture was 
centrifuged. A total of 200 μl of 96-100% ethanol was added 
and the sample was vortexed again for 15 seconds, after which 
it was centrifuged again at 2,500 rpm for 10 minute The mixture 
was transferred into QIAamp Spin Column and centrifuged at 
13,000 rpm for 1 minute. The DNA was then extracted according 
to the manufacturer’s recommendation. The A260/A280 ratio 
of the DNA samples 1.7-1.9, which confirmed that they were 
relatively pure.
Analysis of the genotype
The method of Lindberg et al. [10] was used for DNA ampli-
fi  cation by polymerase chain reaction (PCR). Primers for ampli-
fication of the base sequences are shown in Table 2. The Total 
PCR reagent reaction volume was 25 μl, consisting of g-DNA 
2 μl, Taq polymerase (Takara, Japan) 0.1 μl, dNTP 2 μl (100 
uM), 10 × buffer 2.5 μl, AC D/W 17.4 μl, sense and antisense 
primers 0.5 μl each. PCR conditions were as follows: 94
oC and 
5 minutes for pre-denaturation, followed by 30 cycles of 94
oC 
denaturation for 30 seconds, 56 annealing 
oC for 30 seconds 
and 72
oC synthesis for 1 minute, and finally 72
oC extension 
for 10 minutes. The genotype of MDR1 1236C > T (assay ID: 
C__7586662_10), ABCG2 421C > A (assay ID: C__15854163_70) 
and ABCC2 1249G > A (assay ID: C__22272980_20) SNPs was 
analyzed by established TaqMan Genotyping Assays (Applied 
Biosystems).
Statistical analysis
Alleles of modified single nucleotide polymorphism (SNP) 
and the frequency of a genotype were evaluated by Chi-square 
test with deviation from Hardy-Weinberg equilibrium. Statistical 
meanings of linkage disequilibrium between pairs of SNPs were 
evaluated by the Fischer’s exact test. The result was expressed as 
number or percentage (%), and SPSS program (SPSS Ver 19.0, 
Chicago, IL, USA) was used for all statistical analysis of the data. 
Logistic regression was used for correlation by each genotype 
in the responder and non-responder group after administering 
midazolam. Statistical significance was set as P < 0.05.
Results
A total of 193 patients were enrolled in this study. The average 
age was 7.5-years-old, the average height was 123.5 cm and the 
average weight was 27.6 kg (Table 3).
When anxiety degree was measured by mYPAS before 
administering midazolam, activity was more than 3 in 18 
patients, vocalization was more than 4 in 21 patients, emotional 
expressivity was more than 3 in 35 patients and arousal was more 
than 3 in 15 patients. Twenty-five patients were applicable to two 
Table 2. Demographic Data and Midazolam Plasma Concentration 
Levels
Responder 
(N = 154)
Non-responder
(N = 39)
M : F
Age (yr)
B wt (kg)
Ht (cm)
Midazolam plasma
  concentration (ng/ml)
80 : 74
7.2 ± 2.6
25.8 ± 10.4 
122.7 ± 19.2
83. 4 ± 31.5
18 : 21
7.6 ± 2.9
28.9 ± 9.9
124.6 ± 19.4
81.6 ± 34.2
Values are means ± SD or numbers.335 www.ekja.org
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items or more and their average age was 6.8-years-old (Table 4).
After administering midazolam, a total of 39 patients showed 
anxiety and excitement (20.2%). Activity was more than 3 in 21 
patients, vocalization was more than 4 in 13 patients, emotional 
expressivity was more than 3 in 16 patients and arousal was 
more than 3 in 17 patients. Eighteen patients were applicable to 
two items or more (Table 4).
Continuously high scores before and after administering 
midazolam were shown in 4 patients for activity, 4 patients 
for vocalization, 2 patients for emotional expressivity and in 4 
patients for arousal. Among them, 5 patients were classified into 
the non-responder group (5, 7, 8, 9, and 12-years-old). Stable 
states before administering and high scores after administering 
midazolam were shown in 13 patients for activity, 14 patients 
for vocalization, 8 patients for emotional expressivity and in 10 
patients for arousal.
After administrating midazolam, 43 patients showed smiling 
or laugh and no patient among them was classified into the 
non-responder group.
To measure the concentration of midazolam, blood samples 
were collected after inducing anesthesia. The average con-
centration was 83.4 ng/ml in the responder group and 81.6 ng/
ml in the non-responder group. For estimation of a haplotype 
in three genotypes of 1236C > T, 2677G > T/A, 3435C > T in 
MDR-1 gene, TGC, CAC, CGC, TTT were mainly generated and 
the frequency in each group was shown in Table 5. 
When midazolam was administered as pre-treatment of 
anesthesia to children between 2 and 12 years old with stra-
bismus surgery, a total of 39 patients (20.2%) showed anxiety 
and excitement without sedation. Genetic polymorphism and 
adverse reactions after administrating midazolam were not 
correlated (P = 0.98 or 0.99).
Discussion
Midazolam is commonly used for premedication of anesthesia 
or as sedative in children. When it is used in the clinical field, 
an unexpected reaction can sometimes occur. According to a 
previous study, only 86% of children administered with mida-
zolam before anesthesia showed appropriate sedation for mask 
ventilation [11]. In other studies, 14.1% of children, who were 
administered with 0.5 mg of midazolam, showed severe anxiety 
and excitement but the rate was 20.2% in this clinical study so 
it was more than previous studies [4]. Kain et al. applied 0.5 
mg/kg of midazolam per oral but 0.1 mg/kg of midazolam 
was injected intravenously in this study and the standards to 
classify the responder and non-responder group were different 
so this may cause the difference in the results. In addition, Kain 
et al. reported that adverse reactions of midazolam increased 
as a patient was more emotional, more worried and younger. 
However, the average age of patients, who showed high scores 
in mYPAS before administrating midazolam, was not low 
and 5 of them were classified into the non-responder group 
after administrating midazolam in this study. The age of each 
patient was evenly distributed so it was different to the previous 
studies. The difference might be caused by the difference of the 
standards to classify after administering a drug and observing. 
In other words, a patient was classified by scores of every item 
after oral administration time after time in previous studies but 
a patient was classified into a non-responder group when he (or 
she) was applicable to even one item after measuring scores for 
each item in this study, which may lead to the difference. 
Toll-Sander et al. [12] studied the relationship between 
mida  zolam and p-glycoprotein and reported that midazolam 
was very permeable in p-glycoprotein substrate. Therefore, 
Table 3. Primer and Probe Sequences for MDR1 2677G > T, 2677G > A, 3435C > T 
SNP Primers Probe
MDR1 2677G > T
MDR1 2677G > A
MDR1 3455C > T
5’-GAAATGAAAATGTTGTCTGGACAAGCA-3’
5’-CTTAGAGCATAGTAAGCAGTAGGGAGT-3’
5’-GAAATGAAAATGTTGTCTGGACAAGCA-3
5’-CTTAGAGCATAGTAAGCAGTAGGGAGT-3
5’-CTGTTTGACTGCAGCATTGCT-3’
5’-ATGTATGTTGGCCTCCTTTGCT-3’
VIC-TTCCCAGCACCTTC
FAM-TTCCCAGAACCTTC
VIC-TTCCCAGCACCTTC
FAM-CTTCCCAGTACCTTC
VIC-CCCTCACGATCTCTT
FAM-CCCTCACAATCTCTT
Table 4. Incidence of Non-responder in the Study Subjects
Before 
midazolam
5 minutes after 
midazolam injection
Activity ≥ 3 
Vocalization ≥ 4
Emotional Expressivity ≥ 3
Arousal ≥ 3
18 (9.3)
21 (10.8)
35 (18.1)
15 (7.7)
21 (10.8)
13 (6.7)
16 (8.2)
17 (8.8)
Values are number (% of total patients).
Table 5. Numbers and Frequencies of MDR1 Haplotype
Responder Nonresponder
P value
Number (%) Number (%)
CAC
CGC
TGC
TTT
55 (0.182)
68 (0.225)
62 (0.205)
101 (0.334)
13 (0.169)
13 (0.169)
17 (0.221)
28 (0.364)
0.99
0.98
0.99
0.99336 www.ekja.org
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p-glycoprotein is important to show the effect of midazolam 
and genetic polymorphism of p-glycoprotein was assumed 
to show the difference in the effect of midazolam but was 
not confirmed in this study. If the role of p-glycoprotein did 
not crucially change despite the genetic polymorphism, the 
difference in clinical signs after administering midazolam could 
not be explained. For this reason, further studies are required.
Walbergh et al. [13] reported that the maximum effect of mida  -
zolam was shown in 11 minutes when 0.1 mg/kg midazolam 
was administered through the nasal cavity and the average 
blood concentration was 72.2 ng/ml. In our study, the average 
blood concentration was 80 ng/ml. The blood was collected 6 
minutes later after administering midazolam so the concentration 
may have been higher than in previous reports. Intravenous 
injection could be also a factor for the difference. However, the 
concentration of midazolam between the responder and non-
responder group was not different so a different reaction by the 
blood concentration was difficult to explain. 
The most common reaction was a laugh in adverse reactions 
after administrating a drug and the specificity of genetic 
polymorphism was not found. Although the specificity was 
found, it was not harmful or significant clinically. Therefore, 
polymorphism of other genes was not needed.
In this clinical study, there were several limitations. Other 
genetic polymorphisms could be predicted although it was 
not studied in this study. A receptor of midazolam is GABAA 
receptor and γ2 subunit is essential for modification of binding 
sites. In previous studies, a sleeping effect of benzodiazepine 
did not change but anxiety was higher when γ2 subunit of 
GABAA was not present [14]. Therefore, genetic polymorphism 
of GABRG2, which encodes γ2 subunit of the GABAA receptor, 
should be studied. The other limitation was a standard of 
classification, which when changed led to a correlation between 
genetic polymorphism and reactions for midazolam.
To conclude, when anxiety was measured by mYAS after 
intravenous injection of 0.1 mg/kg midazolam, genetic 
polymorphism of MDR1 was not found in the non-responder 
group compared to the responder group. However, further 
studies are required to find correlations with other genetic 
polymorphisms.
Acknowledgements
This study is supported by Seoul National University Hospital 
Grant (0420080990).
References
1. Bae JH, Koo BW, Kim S, Lee D, Lee ET, Kang C. The effects of mida-
zolam administered postoperatively on emergence agitation in 
pediatric strabismus surgery. Korean J Anesthesiol 2010; 58: 45-9.
2. Kain ZN, Caldwell-Andrews AA, Maranets I, McClain B, Gaal D, 
Mayes LC, et al. Preoperative anxiety and emergence delirium and 
postoperative maladaptive behaviors. Anesth Analg 2004; 99: 1648-
54.
3. Golparvar M, Saghaei M, Sajedi P, Razavi SS. Paradoxical reaction 
following intravenous midazolam premedication in pediatric 
patients - a randomized placebo controlled trial of ketamine for 
rapid tranquilization. Paediatr Anaesth 2004; 14: 924-30.
4. Kain ZN, MacLaren J, McClain BC, Saadat H, Wang SM, Mayes 
LC, et al. Effects of age and emotionality on the effectiveness of 
midazolam administered preoperatively to children. Anesthesiology 
2007; 107: 545-52.
5. Hall RC, Zisook S. Paradoxical reactions to benzodiazepines. Br J 
Clin Pharmacol 1981; 11 Suppl 1: 99S-104S.
6. Short TG, Forrest P, Galletly DC. Paradoxical reactions to benzodia-
zepines--a genetically determined phenomenon? Anaesth Intensive 
Care 1987; 15: 330-1.
7. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the 
MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004; 26: 
180-5.
8. Lazarowski A, Czornyj L. Potential role of multidrug resistant pro-
teins in refractory epilepsy and antiepileptic drugs interactions. 
Drug Metabol Drug Interact 2011; 26: 21-6.
9. Choi HJ, Cho HY, Ro H, Lee SH, Han KH, Lee H, et al. Polymorphisms 
of the MDR1 and MIF genes in children with nephrotic syndrome. 
Pediatr Nephrol 2011; 26: 1981-8.
10. Lindberg AM, Polacek C, Johansson S. Amplification and cloning 
of complete enterovirus genomes by long distance PCR. J Virol 
Methods 1997; 65: 191-9.
11. Cote CJ, Cohen IT, Suresh S, Rabb M, Rose JB, Weldon BC, et al. 
A comparison of three doses of a commercially prepared oral 
midazolam syrup in children. Anesth Analg 2002; 94: 37-43.
12. Tolle-Sander S, Rautio J, Wring S, Polli JW, Polli JE. Midazolam ex  hibits 
characteristics of a highly permeable P-glycoprotein substrate. 
Pharm Res 2003; 20: 757-64.
13. Walbergh EJ, Wills RJ, Eckhert J. Plasma concentrations of mida  zolam 
in children following intranasal administration. Anesthesiology 1991; 
74: 233-5.
14. Chandra D, Korpi ER, Miralles CP, De Blas AL, Homanics GE. GABAA 
receptor gamma 2 subunit knockdown mice have enhanced anxiety-
like behavior but unaltered hypnotic response to benzodiazepines. 
BMC Neurosci 2005; 6: 30.